Researchers discover incredible HULLK that controls prostate cancer progression

by University of Virginia Health SystemDan Gioeli, Ph.D., of the University of Virginia School of Medicine, has identified a key to controlling the growth and progression of prostate cancer, the secon

Updated on: June 19,2024 6

Researchers discover incredible HULLK that controls prostate cancer progression

by University of Virginia Health SystemDan Gioeli, Ph.D., of the University of Virginia School of Medicine, has identified a key to controlling the growth and progression of prostate cancer, the secon

Updated on:June 19,2024 6

Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers

Updated on: January 08,2024 10

Team establishes a large collection of cholangiocarcinoma models for preclinical drug evaluation and biomarker discovery

by Vall d'Hebron Institute of OncologyCholangiocarcinomas (CCAs) are a highly aggressive and diverse group of malignancies of the biliary tract that currently account for 15% of all liver cancers

Updated on:January 08,2024 10

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient

Updated on: February 18,2024 6

FDA Approves Two Cell-Based SCD Gene Therapies

February 2024The U.S. Food and Drug Administration (FDA) approved exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) for the treatment of sickle cell disease (SCD) in patient

Updated on:February 18,2024 6

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l

Updated on: January 30,2024 14

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l

Updated on:January 30,2024 14

A new targeted treatment shows promise for select patients with stomach cancer

byWeill Cornell Medical CollegeCredit: Pixabay/CC0 Public DomainAn international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, has found tha

Updated on: January 29,2024 13

A new targeted treatment shows promise for select patients with stomach cancer

byWeill Cornell Medical CollegeCredit: Pixabay/CC0 Public DomainAn international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, has found tha

Updated on:January 29,2024 13

New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

by Society of Nuclear Medicine and Molecular ImagingGraphical abstract. Credit:Journal of Nuclear Medicine(2022). DOI: 10.2967/jnumed.121.263177A novel PET radiotracer can accurately asses

Updated on: January 11,2024 13

New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

by Society of Nuclear Medicine and Molecular ImagingGraphical abstract. Credit:Journal of Nuclear Medicine(2022). DOI: 10.2967/jnumed.121.263177A novel PET radiotracer can accurately asses

Updated on:January 11,2024 13

A calculator to predict benefit from adjuvant transarterial chemoembolization for hepatocellular carcinoma

by First Hospital of Jilin UniversityVisual Abstract. Credit: Wei-Yue Chen, Jian-Song Ji, Tian Yang, et al.Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fou

Updated on: February 20,2024 20

A calculator to predict benefit from adjuvant transarterial chemoembolization for hepatocellular carcinoma

by First Hospital of Jilin UniversityVisual Abstract. Credit: Wei-Yue Chen, Jian-Song Ji, Tian Yang, et al.Hepatocellular carcinoma (HCC) is the most commonly diagnosed cancer of the liver and the fou

Updated on:February 20,2024 20

Study: More paid sick leave results in more cancer screenings

by Tulane UniversityCredit: Unsplash/CC0 Public DomainFor most Americans, the two major obstacles to proper medical care are time and money. And while insurance can sometimes reduce health care c

Updated on: February 18,2024 14

Study: More paid sick leave results in more cancer screenings

by Tulane UniversityCredit: Unsplash/CC0 Public DomainFor most Americans, the two major obstacles to proper medical care are time and money. And while insurance can sometimes reduce health care c

Updated on:February 18,2024 14

Legalization of medical marijuana beneficial for cancer patients

by Elana GotkineLegalization of medical marijuana is associated with a reduction in opioid dispensing and pain-related hospital events among adults receiving treatment for newly diagnosed cancers, acc

Updated on: February 20,2024 18

Legalization of medical marijuana beneficial for cancer patients

by Elana GotkineLegalization of medical marijuana is associated with a reduction in opioid dispensing and pain-related hospital events among adults receiving treatment for newly diagnosed cancers, acc

Updated on:February 20,2024 18

New delivery strategy may improve chemotherapy for acute myeloid leukemia

byWileyCNL augments the efficacy of cytarabine/venetoclax treatment in in vivo AML models. (A–C) Bioluminescence images (A), their quantification (B) and survival of MOLM-13 Luc-YFP bearing NRG

Updated on: January 11,2024 15

New delivery strategy may improve chemotherapy for acute myeloid leukemia

byWileyCNL augments the efficacy of cytarabine/venetoclax treatment in in vivo AML models. (A–C) Bioluminescence images (A), their quantification (B) and survival of MOLM-13 Luc-YFP bearing NRG

Updated on:January 11,2024 15

Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say

byH. Lee Moffitt Cancer Center & Research InstituteCancer cell during cell division. Credit: National Institutes of HealthThe recent U.S. Food and Drug Administration approval of lifileucel,

Updated on: August 03,2024 0

Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say

byH. Lee Moffitt Cancer Center & Research InstituteCancer cell during cell division. Credit: National Institutes of HealthThe recent U.S. Food and Drug Administration approval of lifileucel,

Updated on:August 03,2024 0

Study finds nearly half of top cancer centers required universal masking during last winter's COVID-19 surge

byTulane UniversityCredit: Unsplash/CC0 Public DomainNearly half of the nation's National Cancer Institute (NCI)-designated cancer centers required universal masking in key clinical areas du

Updated on: August 27,2024 0

Study finds nearly half of top cancer centers required universal masking during last winter's COVID-19 surge

byTulane UniversityCredit: Unsplash/CC0 Public DomainNearly half of the nation's National Cancer Institute (NCI)-designated cancer centers required universal masking in key clinical areas du

Updated on:August 27,2024 0